GRIFOLS, S.A. Patent applications |
Patent application number | Title | Published |
20160114922 | METHOD FOR THE ASEPTIC FILLING OF A BAG - Method for the aseptic filling of a bag with a pharmaceutical product or liquid which comprises the following steps: a) a first step in which the cap is inserted in the inlet of the bag; b) a second step in which said cap is raised and the pharmaceutical product or liquid concerned is introduced; c) a third step in which the cap is re-inserted in the inlet of the bag; and d) a fourth step in which the cap and the inlet of the bag are welded. | 04-28-2016 |
20150250987 | THERAPEUTIC DELIVERY DEVICES, SYSTEMS, AND METHODS - Devices, systems, and methods for delivery of therapeutics, in particular thrombolytic agents, in particular plasmin, are provided. The devices, systems, and methods also provide for occlusion of a vessel or graft distal and/or proximal to a treatment zone. Also provided are devices, systems, and methods that trap emboli. | 09-10-2015 |
20150011962 | CONTAINER FOR BLOOD DERIVATIVE PRODUCTS - A hermetically-sealed plastics container for blood derivative products is provided. The container may have an internal surface and an external surface, characterised in that it comprises an RFID inlay between the internal surface and the external surface. | 01-08-2015 |
20140163101 | CAPRYLATE VIRAL DEACTIVATION - Described herein are methods for inactivating viruses using caprylate in solutions containing albumin. | 06-12-2014 |
20140162299 | RAPID AND ACCURATE ANALYSIS OF PROTEIN SIALYLATION - The invention relates to methods and kits for the analysis of the sialylation of gluco-proteins. The samples of gluco-protein are incubated separately under three conditions: with beta-galactosidase, with beta-galactosidase+alpha-sialidase, and without an enzyme. After the enzyme treatment, high performance anion exchange chromatography with pulsed amperometric detection (HPAEC PAD) is used to make a quantitative determination of the total galactose in the sample, the non sialylated galactose and the exogenous galactose in the medium. The determination of said values makes it possible to deduce the percentage of sialylation of the gluco-protein. | 06-12-2014 |
20140113355 | PROCESS FOR OBTAINING AN IgG COMPOSITION THROUGH HEAT TREATMENT - A process for obtaining an IgG composition involves heat treatment. This process obtains an IgG composition from an IgG solution partly purified from human plasma, in which by applying intermediate heat treatment and without using reagents to precipitate high molecular weight aggregates/polymers and/or proteins virtually total elimination of the IgG polymers generated during the process is achieved. Furthermore this process offers high productivity, lower production costs and is easy to implement in comparison with the processes of the know art. In addition to this, by using this process stability is imparted to the final product in liquid. | 04-24-2014 |
20140100507 | PRIMING ANTICOAGULANT LINE FOR BLOOD EXTRACTION - Methods and devices are described for reducing anticoagulant dilution of collected blood components during blood collection. | 04-10-2014 |
20140026593 | THAWING VESSEL FOR BIOLOGICAL PRODUCTS - Described herein are devices and methods for thawing frozen biological products efficiently without harming the products. | 01-30-2014 |
20130236559 | METHOD AND DEVICE FOR TREATING BLOOD CHOLESTEROL DISORDERS - A method and device for treating cholesterol disorders includes administering at least one treatment regime including two or more rounds of plasmapheresis to a patient having abnormal total cholesterol, abnormal LDL levels and/or abnormal HDL levels prior to treatment. Treatment according to the method results in decreased LDL levels in patients having abnormal LDL levels and increased HDL levels in patients having abnormal HDL levels. Each subsequent round of plasmapheresis is conducted weekly, but no more than twice per week. | 09-12-2013 |
20130164815 | PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION - Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluded at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy. | 06-27-2013 |
20130164273 | REVERSIBLY INACTIVATED ACIDIFIED PLASMIN COMPOSITION - The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. | 06-27-2013 |
20130019993 | DEVICE FOR EMPTYING A BLOOD PRODUCT BAG - Device for emptying a bag containing a frozen blood-derived product, including: a cutting device; an extractor for the product, a hopper for receiving the product, a device for transporting the bag from a receiving area to the plasma extractor, this transporting device including a robotic arm with a gripper which, in turn, includes: two catching arms, each defining at least a distal end and a proximal end, and an actuator, in which the actuator controls a mechanism for modifying the distance separating the distal ends of the gripper arms to catch the bag by its lower surface | 01-24-2013 |
20120045389 | METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE TRANSFER TO MONOCYTES AND MACROPHAGES - The present invention provides a biosafe and useful vector to transfer genetic material to CD14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells. | 02-23-2012 |
20110275570 | PROCESS FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OF A COMPLEX OF FACTOR VIII/VON WILLEBRAND FACTOR AND USE OF THE SAME - A method of treating a patient suffering from Haemophilia A and/or Von Willebrand's disease involves administering the patient a concentrate of Von Willebrand Factor (VWF) or a complex of Factor VIII/VWF prepared by creating a solution of VWF or a complex of Factor VIII/VWF containing VWF at a concentration of up to 12 IU VWF:RCo/ml and a VWF/Factor VIII ratio of 0.4 or more, and nanofiltering that starting solution through a filter of pore size of about 35 nm or smaller. The resulting VWF retains high molecular weight multimers. | 11-10-2011 |
20110087566 | ELECTRONIC SYSTEM FOR THE MANAGEMENT OF THE REPLENISHMENT OF FILLING OF PLANT STORES IN HOSPITALS - System for the replenishment and filling of stores which comprises at least one full function device (FFD) capable of bidirectional wireless communication with at least one RFD and is capable of data processing, and at least one reduced function device (RFD) capable of bidirectional wireless communication, characterised in that said RFD comprises a push-button, an RF transceiver, an indicator device and a battery and also emits a restocking request signal to the FFD when said button is pressed. | 04-14-2011 |
20110045455 | SUSPENSION MEDIUM FOR RED BLOOD CELLS - The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks. | 02-24-2011 |
20110027891 | MAMMALIAN CELL CULTURE MEDIA WHICH COMPRISE SUPERNATANT FROM COHN FRACTIONATION STAGES AND USE THEREOF - The present invention relates to mammalian cell culture media which comprise supernatant from some of the fractions of human plasma fractionation according to the Cohn method, more specifically, the supernatant of fractions I and II+III. When said supernatant is added as a culture medium supplement it provides various nutrients and factors for the effective maintenance and/or proliferation of the cultured mammalian cells. In addition, the present invention relates to the preparation process and use of said medium in the culture of mammalian cells. | 02-03-2011 |
20100331261 | USE OF ALPHA-1-ANTITRYPSIN FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME - The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days. | 12-30-2010 |
20100312274 | DEVICE FOR THE APPLICATION OF FIBRIN ADHESIVE - A device for the application of two components of fibrin adhesive at a treatment site comprising a support for syringes comprising two parallel cylindrical housings to receive corresponding syringes and a plunger connecting member, characterised in that the said syringe support comprises a passage for insertion of the said plunger connecting member, the said passage being located in the space defined between the cylindrical housings of the said syringe support, the said plunger connector having a zone with a suitable geometry to slide within the said passage and in that the transverse cross-section of the said passage of the syringe support has a maximum opening at the ends and a minimum opening in the central part. | 12-09-2010 |
20100221765 | MICROTUBE READER DEVICE FOR THE ANALYSIS OF BLOOD SAMPLES - The invention comprises taking colour pictures of back-lighted analysis microtubes and using the colour information in the images to identify areas of the image which are relevant for interpreting the result of other possible artefacts, as well as detecting abnormal samples and/or reactions characterised by changes in the colour properties of the reaction. | 09-02-2010 |
20100180698 | DEVICE FOR THE AUTOMATIC TAKING OF SAMPLES OF LIQUID FROM COLLECTION CONTAINERS AND METHOD FOR PERFORMING SAID SAMPLE TAKING - Device for taking samples of liquid from a collection container, characterised in that it comprises a support for liquid sample collection containers; a support for a set of containers into which the sample of liquid will be deposited; a support for connection elements; a container handling mechanism; and a device for inserting the containers into which the sample of liquid will be deposited into the connection element. | 07-22-2010 |
20100159017 | COMPOSITION OF BIOCOMPATIBLE MICROPARTICLES OF ALGINIC ACID FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS BY INTRAVENOUS ADMINISTRATION - The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously. | 06-24-2010 |
20090293644 | APPARATUS FOR AUTOMATIC ANALYSIS OF SAMPLES ON GEL CARDS - The apparatus comprises a single transportable structure provided with several separate compartments located in a vertical stack within a cabinet, with means for the vertical transport of gel cards, means for the transport of units for moving the cards and pipetting probes, being displaceable to the entire transverse cross-section of the compartments in at least two of the vertical compartments or floors through moving along coordinate axes X, Y, Z at right-angles, and control means so that automatic functioning can take place simultaneously with manual actions to load and unload the necessary materials (samples, reagents, cards, wash solutions and waste solutions) in a random manner. | 12-03-2009 |
20090176709 | PROCESS FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OR A COMPLEX OF FACTOR VIII/VON WILLEBRAND FACTOR AND USE OF THE SAME - The process is characterised by the preparation of a solution of Von Willebrand Factor or a complex of Factor VIII/Von Willebrand Factor which contains VWF and a concentration of up to 12 IU VWF:RCo/ml and a Von Willebrand Factor/Factor VIII ratio of 0.4 or more; and then proceeding with nanofiltration of the solution prepared in a) through a filter having a pore size of less than 35 nanometres. | 07-09-2009 |
20090111740 | USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF PATIENTS SUFFERING FROM COGNITIVE DISORDERS - The present invention relates to the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. In particular, the invention relates to methods of treating patients suffering from cognitive disorders, in which the mode of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of Aβ in the patient's blood. | 04-30-2009 |
20080274974 | PROCESS FOR REMOVING VIRUSES IN FIBRINOGEN SOLUTIONS AND FIBRINOGEN OBTAINED BY SAID PROCESS - A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm. | 11-06-2008 |
20080232986 | TUBULAR PUMP - The invention provides the arrangement of a resilient and flexible tubular element, with shape memory, which contains the product to be metered and which receives an action of limited compression of the walls thereof, in such a way that there is no contact between the internal walls of the opening of the tubular element which propels the product, in such a way that the product supply and discharge are controlled by respective valves situated before and after the compressible tubular metering element. | 09-25-2008 |